In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nippon Chemiphar Co., Ltd.

http://www.chemiphar.co.jp/english/

Latest From Nippon Chemiphar Co., Ltd.

IFC And Nippon Chemiphar Ally In Asia, Middle East And Africa

Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost local production of generics in Asia, the Middle East and Africa, as part of efforts to reduce reliance on imports.

Deals Manufacturing

Chemiphar Revises Forecasts Up Following Q3 Performance

Three strong quarters in a row have prompted Nippon Chemiphar to revise up its FY2021 forecasts, thanks to strong sales of generic drugs launched in FY2020 and June 2021, as well as an increase in demand due to quality control issues faced by competitors.

Sales & Earnings Generic Drugs

Consolidation And COVID See Off-Patent Industry Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

Sales & Earnings Biosimilars

Nippon Chemiphar’s Generics Business Continues To Recover

Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic. 

Sales & Earnings Generic Drugs
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Laboratory Testing Services
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
UsernamePublicRestriction

Register